Inovio's Influenza Vaccine Shows Potential, Shares Rally
Zacks Investment Research | Jan 23, 2018 08:31PM ET
Inovio Pharmaceuticals, Inc.’s (NASDAQ:INO) shares increased 22.6% after it announced that its universal influenza vaccine has demonstrated protective antibody responses against all major strains of H1N1 influenza viruses from the last 100 years. Although the candidate is in pre-clinical study and response were reported against a particular virus, investors were encouraged by the universal nature of response.
Shares of the company have declined 10.4% in the past year, underperforming the industry ’s gain of 8.8% in that period.
Inovio’s synthetic vaccine, a collection of synthetic DNA antigens, has been tested in multiple animal models including mice, guinea pigs and non-human primates. The vaccine also demonstrated 100% protection in the ferret model, the gold standard in animal models for evaluating influenza vaccines.
Globally efforts have been taken to create a universal flu vaccine, which can protect against every strain of influenza viruses. The currently available vaccines work against only three or four strains, which makes it difficult for health officials to effectively treat the disease by predicting the correct strain of virus in a particular season.
Data published in the journal Vaccine demonstrated that Inovio’s ASPIRE technology platform maybe capable of producing a universal flu vaccine, which can be effective amid seasonal vaccine changes, thus providing continued immune protection.
Per CDC estimates, 56,000 died in 2012-13 due to causes related to influenza while WHO estimated that the seasonal flu vaccines presently have a market size of $3.8 billion. Although, the idea is far-fetched, a potential universal flu will certainly help more number of patients and boost the company’s prospects.
The company believes that this novel strategy can be developed further to protect patients against viruses of dengue, RSV and HIV.
BiondVax Pharmaceuticals Ltd.;s (NASDAQ:BVXV) pipeline candidate, M-001, is also being developed as a universal flu vaccine. Moreover, Emergent BioSolutions Inc. (NYSE:EBS) is also developing FLU-IGIV, a human polyclonal antibody, in a phase II study to treat influenza A virus infection. We also remind investors that the FDA had approved the line expansion of GlaxoSmithKline plc’s (NYSE:GSK) influenza vaccine, FluarixQuadrivalent, to include infants six months or older earlier this month.
Get The News You Want
Inovio Pharmaceuticals, Inc. Price
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.